IMUNOVIR Tablet Ref.[8507] Active ingredients: Inosine pranobex

Posology

Adults and the Elderly

The recommended dosage is 50mg/kg–100mg/kg of body weight usually 3g/day up to a maximum of 4g/day, administered orally in 3-4 equally divided doses during waking hours.

Mucocutaneous herpes simplex: 1 g administered orally 4 times daily, for 7-14 days.

Genital warts: 1g administered orally 3 times daily, for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser.

Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, up to a maximum of 3-4 g, in divided doses every 4 hours, with regular monitoring to evaluate patient status and requirement for extended treatment.

The weight of the patient and the severity of the disease are important factors in determining the dosage.

Children

No information is available in children.

Method of administration

Oral use.

To make ingestion easier, the tablets may be crushed and dissolved in a small amount of flavoured liquid at the time of administration.

There has been no experience of overdose with Imunovir. However, serious adverse effects apart from increased levels of uric acid in the body, seem unlikely in view of the animal toxicity studies. Treatment should be restricted to symptomatic and supportive measures.

5 years.

This medicinal product does not require any special storage conditions.

100 (5 × 20) tablets in transparent, colourless PVC/PVDC blister packs sealed with aluminium foil.

No special requirements.